Effectiveness of drug use evaluation and antibiotic authorization on patients' clinical outcomes, antibiotic consumption, and antibiotic expenditures

American Journal of Infection Control

Volumn 38, Issue 1, 2010, Pages 38-43

  Rattanaumpawan, Pinyo ^a   Sutha, Patama ^a   Thamlikitkul, Visanu ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

antibiotic authorization; antibiotic consumption; Drug use evaluation; imipenem; meropenem; piperacillin tazobactam

Indexed keywords

ANTIBIOTIC AGENT; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ADULT; ANTIBIOTIC AUTHORIZATION; ARTICLE; BACTEREMIA; CONTROLLED STUDY; DRUG COST; DRUG USE; FEMALE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; RESPIRATORY TRACT INFECTION; SKIN INFECTION; SOFT TISSUE INFECTION; TREATMENT DURATION; TREATMENT OUTCOME; URINARY TRACT INFECTION;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG UTILIZATION; DRUG UTILIZATION REVIEW; FEMALE; HEALTH SERVICES RESEARCH; HUMANS; MALE; MIDDLE AGED; ORGANIZATIONAL POLICY; THAILAND;

EID: 74449087190     PISSN: 01966553     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajic.2009.04.288     Document Type: Article

References (19)

1. Roberts A.W., and Visconti J.A. The rational and irrational use of systemic antimicrobial drugs. Am J Hosp Pharm 29 (1972) 828-834
2. McGowan J.E. Antimicrobial resistance in hospital organisms and its relation to antibiotic use. Rev Infect Dis 5 (1983) 1033-1048
3. Monroe S., and Polk R. Antimicrobial use and bacterial resistance. Curr Opin Microbiol 3 (2000) 496-501
4. Barbosa T.M., and Levy S.B. The impact of antibiotic use on resistance development and persistence. Drug Resistance Updates 3 (2000) 303-311
5. Paterson D.L. "Collateral damage" from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis 38 Suppl 4 (2004) S341-S345
6. Alanis A.J. Resistance to antibiotics: are we in the post-antibiotic era?. Arch Med Res 36 (2005) 697-705
7. French G.L. Clinical impact and relevance of antibiotic resistance. Adv Drug Deliv Rev 57 (2005) 1514-1527
8. Dellit T.H., Owens R.C., McGowan Jr. J.E., Gerding D.N., Weinstein R.A., Burke J.P., et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 44 (2007) 159-177
9. Kunin C.M., Lipton H.L., Tupasi T., Sacks T., Scheckler W.E., Jivani A., et al. Social, behavioral, and practical factors affecting antibiotic use worldwide: report of Task Force 4. Rev Infect Dis 9 Suppl 3 (1987) S270-S285
10. Istúriz R.E., and Carbon C. Antibiotic use in developing countries. Infect Control Hosp Epidemiol 21 (2000) 394-397
11. Radyowijati A., and Haak H. Improving antibiotic use in low-income countries: an overview of evidence on determinants. Soc Sci Med 57 (2003) 733-744
12. Thamlikitkul V., Danchaivijitr S., Kongpattanakul S., and Ckokloikaew S. Impact of an educational program on antibiotic use in a tertiary care hospital in a developing country. J Clin Epidemiol 51 (1998) 773-778
13. Sáez-Llorens X., Castrejón de Wong M.M., Castaño E., De Suman O., De Moros D., and De Atencio I. Impact of an antibiotic restriction policy on hospital expenditures and bacterial susceptibilities: a lesson from a pediatric institution in a developing country. Pediatr Infect Dis J 19 (2000) 200-206
14. Ozkurt Z., Erol S., Kadanali A., Ertek M., Ozden K., and Tasyaran M.A. Changes in antibiotic use, cost and consumption after an antibiotic restriction policy applied by infectious disease specialists. Jpn J Infect Dis 58 (2005) 338-343
15. Raveh D., Muallem-Zilcha E., Greenberg A., Wiener-Well Y., Schlesinger Y., and Yinnon A.M. Prospective drug utilization evaluation of three broad-spectrum antimicrobials: cefepime, piperacillin-tazobactam and meropenem. QJM 99 (2006) 397-406
16. Siddiqui S., Hussein K., Manasia R., Samad A., Salahuddin A., Zafar A., et al. Impact of antibiotic restriction on broad spectrum antibiotic usage in the ICU of a developing country. J Pak Med Assoc 57 (2007) 484-487
17. Falagas M.E., Bliziotis I.A., Michalopoulos A., Sermaides G., Papaioannou V.E., Nikita D., et al. Effect of a policy for restriction of selected classes of antibiotics on antimicrobial drug cost and resistance. J Chemother 19 (2007) 178-184
18. Fagon J.Y., Chastre J., Hance A.J., Montravers P., Novara A., and Gibert C. Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. Am J Med 94 (1993) 281-288
19. Burke J.P. Antibiotic resistance-squeezing the balloon?. JAMA 280 (1998) 1270-1271